A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M.
Palandri F, et al.
Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027.
Cancers (Basel). 2023.
PMID: 37894394
Free PMC article.
Overall, 172 patients were alive on ruxolitinib after 5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after 5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after <5 yrs (early death on ruxolitinib, EDR). The cumulative …
Overall, 172 patients were alive on ruxolitinib after 5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib afte …